Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Global Ophthalmology Market - Refractive Disorders Commanded the Largest Market Share
August 10, 2023 04:33 ET
|
Research and Markets
Dublin, Aug. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Ophthalmology Market by Diseases (Age-Related Macular Degeneration, Cataract, Glaucoma), Product Type (Drugs, Equipment, Prescription Glasses...
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray)...
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
August 08, 2023 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
August 08, 2023 07:00 ET
|
Cognition Therapeutics, Inc.
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer’s Disease ...
Survey Reveals 1 In 6 Quebec Parents Have Yet to Take Their Child to the Eye Doctor
August 08, 2023 06:00 ET
|
Essilor® Canada
MONTREAL, Aug. 08, 2023 (GLOBE NEWSWIRE) -- A recent survey conducted by Essilor®, part of EssilorLuxottica a leading global eyecare and eyewear provider1, reveals that children’s eye health and...
Un sondage révèle qu’un parent québécois sur six n’a encore jamais emmené son enfant chez l’optométriste
August 08, 2023 06:00 ET
|
Essilor® Canada
MONTRÉAL, 08 août 2023 (GLOBE NEWSWIRE) -- Une récente étude menée par Essilor®, membre d’EssilorLuxottica, l’un des principaux fournisseurs de soins ophtalmologiques et de lunettes à...
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
August 02, 2023 11:15 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...